American Journal of Cardiology
Volume 88, Issue 10 , Pages 1139-1142 , 15 November 2001

C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease

  • Trine Madsen, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Trine Madsen, MD, Department of Biomedical Science, University of Wollongong, Northfields Ave, Wollongong NSW 2522, Australia.
    • Department of Cardiology, Aalborg Hospital, Aalborg, Denmark
    • ,
  • Helle Aarup Skou, MD

      Affiliations

    • Department of Medicine, Hjørring/Brønderslev Hospital, Aalborg, Denmark
    • ,
  • Vibeke Ellegaard Hansen, MD

      Affiliations

    • Department of Medicine, Hjørring/Brønderslev Hospital, Aalborg, Denmark
    • ,
  • Lars Fog, MD

      Affiliations

    • Department of Cardiology, Aalborg Hospital, Aalborg, Denmark
    • ,
  • Jeppe Hagstrup Christensen, MD

      Affiliations

    • Department ofNephrology, Aalborg Hospital, Aalborg, Denmark
    • ,
  • Egon Toft, MD, DSc

      Affiliations

    • Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark
    • ,
  • Erik Berg Schmidt, MD, DSc

      Affiliations

    • Department of Medicine, Hjørring/Brønderslev Hospital, Aalborg, Denmark

Received 17 April 2001 ,Revised 11 July 2001 ,Accepted 11 July 2001.

References 

  1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  2. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850
  3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  4. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–466
  5. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–235
  6. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation. 1997;96:4204–4210
  7. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855–860
  8. Schmidt EB. n-3 fatty acids and the risk of coronary heart disease. Dan Med Bull. 1997;44:1–22
  9. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(suppl.):343S–348S
  10. Heller A, Koch T, Schmeck J, van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998;55:487–496
  11. Christensen JH, Skou HA, Fog L, Hansen VE, Vesterlund T, Dyerberg J, et al. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation. 2001;103:651–657
  12. Schmidt EB, Pedersen JO, Varming K, Ernst E, Jersild C, Grunnet N, et al. n-3 fatty acids and leukocyte chemotaxis. Effects in hyperlipidemia and dose-response studies in healthy men. Arterioscler Thromb. 1991;11:429–435
  13. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects (implications for reference intervals and epidemiological applications). Clin Chem. 1997;43:52–58
  14. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem. 1999;45:1967–1973
  15. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioi M, Lozniewski A, et al. C-reactive protein and coronary artery disease (additional evidence of the implication of an inflammatory process in acute coronary syndromes). Am Heart J. 1999;137:346–351
  16. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation. 1999;99:2452–2457
  17. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265–271
  18. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71(suppl.):213S–223S
  19. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum. 1997;27:85–97
  20. Endres S, Lorenz R, Loeschke K. Lipid treatment of inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 1999;2:117–120
  21. Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes (a dose-response study with n-3 fatty acids). Am J Clin Nutr. 1999;70:331–337
  22. Brown AJ, Pang E, Roberts DC. Persistent changes in the fatty acid composition of erythrocyte membranes after moderate intake of n-3 polyunsaturated fatty acids (study design implications). Am J Clin Nutr. 1991;54:668–673
  23. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70(suppl.):560S–569S
  24. Schmidt EB, Dyerberg J. n-3 fatty acids and leucocytes. J Intern Med Suppl. 1989;225:151–158
  25. Ernst E, Saradeth T, Achhammer G. n-3 fatty acids and acute-phase proteins. Eur J Clin Invest. 1991;21:77–82

☆ This study was supported by The Danish Heart Foundation and The Medical Resarch Foundation of the County of Northern Jutland, Denmark.

PII: S0002-9149(01)02049-5

American Journal of Cardiology
Volume 88, Issue 10 , Pages 1139-1142 , 15 November 2001

Article Tools

* Image Usage & Resolution